Joe Y Chang, Professor, Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:
“Join us at PTCOG 63 to explore cutting-edge particle therapy and novel Phase III randomized studies comparing IMRT and IMPT.
With advancements in LET optimization, immune modulation, we are moving PT into the new era.”
More posts featuring Joe Y Chang on OncoDaily.
